EPISODE · Jan 8, 2026 · 1H 26M
Ep192: Kate Haviland on Following the Science to Precision Immunology
from The Long Run with Luke Timmerman · host Timmerman Report
Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.
What this episode covers
Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.
NOW PLAYING
Ep192: Kate Haviland on Following the Science to Precision Immunology
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m